Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Account Payables (2023 - 2025)

Immunocore Holdings' Change in Account Payables history spans 3 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 75.9% year-over-year to $1.4 million; the TTM value through Dec 2025 reached -$2.5 million, down 133.77%, while the annual FY2025 figure was -$2.5 million, 133.77% down from the prior year.
  • Change in Account Payables for Q4 2025 was $1.4 million at Immunocore Holdings, up from -$287000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $6.0 million in Q2 2023 and bottomed at -$6.9 million in Q2 2025.
  • The 3-year median for Change in Account Payables is $565500.0 (2025), against an average of $620083.3.
  • The largest YoY upside for Change in Account Payables was 244.05% in 2025 against a maximum downside of 254.53% in 2025.
  • A 3-year view of Change in Account Payables shows it stood at $3.8 million in 2023, then skyrocketed by 56.7% to $5.9 million in 2024, then tumbled by 75.9% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Change in Account Payables are $1.4 million (Q4 2025), -$287000.0 (Q3 2025), and -$6.9 million (Q2 2025).